Jaguar Health, Inc. (JAGX)

0,2980 -0,0190 (-5,99%) Börsenschluss: 04:00PM EDT

Jaguar Health, Inc.

200 Pine Street
Suite 400
San Francisco, CA 94104
United States
415 371 8300
https://jaguar.health

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 49

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Ms. Lisa A. Conte	Founder, CEO, President & Director	610,66k	N/A	1959
Dr. Pravin R. Chaturvedi Ph.D.	Chief Scientific Officer & Chair of Scientific Advisory Board	517,91k	N/A	1963
Mr. Jonathan S. Wolin CPA, J.D., M.B.A.	Chief of Staff, Chief Compliance Officer & General Counsel	457,61k	N/A	1962
Dr. Steven R. King Ph.D.	Chief of Sustainable Supply, Ethnobotanical Research & Intellectual Property and Secretary	406,4k	N/A	1958
Ms. Carol R. Lizak M.B.A.	Chief Financial Officer	N/A	N/A	1964
Mr. Peter Hodge	Senior Director of Investor Relations, Business Development & Special Events	N/A	N/A	N/A
Dr. Karen J. Brunke Ph.D.	Executive VP of Corporate & Business Development	N/A	N/A	1953
Mr. David Sesin	Chief Manufacturing Officer	N/A	N/A	N/A
Mr. Ian H. Wendt M.B.A.	Chief Commercial Officer	441,31k	N/A	1968
Dr. Massimo Radaelli M.B.A., Ph.D.	President of Jaguar International	N/A	N/A	1958

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.

Corporate Governance

Jaguar Health, Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.